Neoadjuvant BRAF and MEK inhibitor therapy elicits pathological complete response in stage IIIA non‐small cell lung cancer harboring BRAF V600E mutation: A case report
Abstract In recent years, significant improvement has been made in the management of non‐small cell lung cancer (NSCLC), primarily driven by advances in targeted therapy and immunotherapy. Research on neoadjuvant targeted therapy has also experienced considerable development, primarily directed towa...
Salvato in:
| Autori principali: | , , , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Wiley
2024-08-01
|
| Serie: | Thoracic Cancer |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1111/1759-7714.15409 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|